Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 10/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.49 |
| ▸ | SPR | P35270 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22322792 | 0.89 | CHRM1 (0.48) | CHRM1PDE3BPDE3ASPRELANE | |
| SCHEMBL21858970 | 0.85 | CHRM1 (0.59) | CHRM1SMN1; SMN2 | |
| SCHEMBL30436296 | 0.82 | CHRM1 (0.57) | CHRM1PDE3BPDE3A | |
| SCHEMBL25348205 | 0.82 | SPR (0.49) | SPRELANEALDH1A1SMN1; SMN2 | |
| SCHEMBL21859079 | 0.82 | CHRM1 (0.64) | CHRM1SPR | |
| SCHEMBL21938332 | 0.81 | CHRM1 (0.61) | CHRM1SPR | |
| SCHEMBL28573813 | 0.78 | SPR (0.47) | SPRELANE | |
| SCHEMBL21938331 | 0.78 | CHRM1 (0.40) | CHRM1SPRSMN1; SMN2 | |
| SCHEMBL25348758 | 0.78 | SPR (0.44) | SPRALDH1A1SMN1; SMN2 | |
| SCHEMBL21859083 | 0.78 | CHRM1 (0.66) | CHRM1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122779-B2 | Pyrrolo-pyridazine derivatives as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2024-10-22 | — | — | US | disclosed |
| EP-3867254-B1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-05-31 | — | — | EP | disclosed |
| EP-3867254-B1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-05-31 | — | — | EP | disclosed |
| US-20210340148-A1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-11-04 | — | — | US | disclosed |
| WO-2020079606-A9 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020079606-A9 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020079606-A1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020079606-A1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340148-A1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM5, CHRM2 | CHRM1 1/4885PDE3B 1485/4885PDE3A 877/4885 |
| US-12122779-B2 | Pyrrolo-pyridazine derivatives as muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM5, CHRM2 | CHRM1 1/4885PDE3B 1485/4885PDE3A 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.